Published:Â October 17th 2024Â |Â Updated:Â October 21st 2024
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment
Published:Â September 18th 2024Â |Â Updated:Â September 20th 2024
Multi-Ethnic Study Identifies Ancestry-Specific Genetic Variants that Influence Risk of Multiple Sclerosis
Published:Â September 9th 2024Â |Â Updated:Â September 11th 2024
FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Published:Â August 24th 2024Â |Â Updated:Â August 26th 2024
Vatiquinone Pharmacokinetics Influenced by CYP3A4 Inhibitors and Inducers in Phase 1 Study
Published:Â August 22nd 2024Â |Â Updated:Â August 23rd 2024
Novel Cell-Based Assay Enhances Detection of Autoantibodies in Neurological Disorders
Published:Â August 6th 2024Â |Â Updated:Â August 15th 2024
The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD